Correlation Between Appili Therapeutics and Berkshire Hathaway

Can any of the company-specific risk be diversified away by investing in both Appili Therapeutics and Berkshire Hathaway at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Appili Therapeutics and Berkshire Hathaway into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Appili Therapeutics and Berkshire Hathaway CDR, you can compare the effects of market volatilities on Appili Therapeutics and Berkshire Hathaway and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Appili Therapeutics with a short position of Berkshire Hathaway. Check out your portfolio center. Please also check ongoing floating volatility patterns of Appili Therapeutics and Berkshire Hathaway.

Diversification Opportunities for Appili Therapeutics and Berkshire Hathaway

-0.18

Correlation Coefficient

Appili Therapeutics  Berkshire Hathaway

Good diversification

The 3 months correlation between Appili and Berkshire is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Appili Therapeutics and Berkshire Hathaway CDR in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Berkshire Hathaway CDR and Appili Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Appili Therapeutics are associated (or correlated) with Berkshire Hathaway. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Berkshire Hathaway CDR has no effect on the direction of Appili Therapeutics i.e., Appili Therapeutics and Berkshire Hathaway go up and down completely randomly.

Pair Corralation between Appili Therapeutics and Berkshire Hathaway

Assuming the 90 days trading horizon Appili Therapeutics is expected to generate 8.36 times more return on investment than Berkshire Hathaway. However, Appili Therapeutics is 8.36 times more volatile than Berkshire Hathaway CDR. It trades about 0.05 of its potential returns per unit of risk. Berkshire Hathaway CDR is currently generating about 0.19 per unit of risk. If you would invest  3.50  in Appili Therapeutics on December 23, 2024 and sell it today you would earn a total of  0.00  from holding Appili Therapeutics or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Appili Therapeutics  vs.  Berkshire Hathaway CDR

Appili Therapeutics

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Appili Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Appili Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Berkshire Hathaway CDR

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Berkshire Hathaway CDR are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of very abnormal basic indicators, Berkshire Hathaway displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Appili Therapeutics and Berkshire Hathaway

The main advantage of trading using opposite Appili Therapeutics and Berkshire Hathaway positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Appili Therapeutics position performs unexpectedly, Berkshire Hathaway can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Berkshire Hathaway will offset losses from the drop in Berkshire Hathaway's long position.

The idea behind Appili Therapeutics and Berkshire Hathaway CDR pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.